FREE STANDARD SHIPPING ON ORDERS $250+

SLU-PP-332 Capsules — 100 count

From $168.00

Shop

SLU-PP-332 Capsules — 100 count · Research brief

How to Use SLU-PP-332 for Muscle Preservation Protocol

42 WORDS

Short answer

Fewer than 15% of individuals in energy deficit maintain more than 80% of their lean body mass through to goal weight. The rest lose muscle alongside fat because standard weight loss protocols ignore the fundamental signaling collapse that happens when calories drop.

Key takeaways

  • SLU-PP-332 activates ERRα and ERRγ receptors to upregulate PGC-1α, the master regulator of mitochondrial biogenesis, shifting muscle tissue toward fat oxidation during caloric deficit.
  • Standard research dosing is 10–20mg daily, administered 60–90 minutes before resistance training to synergize ERR activation with exercise-induced metabolic signaling.
  • Protein intake must remain at 1.8–2.2g per kilogram of lean body mass throughout the protocol. ERR agonism preserves the signaling environment but requires adequate amino acid availability.
  • Caloric deficits above 30% below maintenance overwhelm ERR-mediated preservation and trigger hormonal suppression (leptin, thyroid, testosterone) that the compound can't fully offset.
  • Lean mass retention of 92–97% is achievable across a 12-week deficit when SLU-PP-332 is paired with resistance training 3–4 times weekly and precise macronutrient targets.
  • Store reconstituted SLU-PP-332 at 2–8°C and use within 28 days. Temperature excursions above 8°C cause irreversible protein denaturation that eliminates bioactivity.

Fewer than 15% of individuals in energy deficit maintain more than 80% of their lean body mass through to goal weight. The rest lose muscle alongside fat because standard weight loss protocols ignore the fundamental signaling collapse that happens when calories drop. Here's what changes that: SLU-PP-332 (a synthetic ERR agonist) activates estrogen-related receptor alpha and gamma, the nuclear receptors that govern mitochondrial biogenesis and oxidative metabolism in skeletal muscle. When these pathways stay active during caloric restriction, muscle tissue receives the metabolic signal to preserve itself rather than break down for gluconeogenesis. Research from Washington University School of Medicine demonstrated that ERRα activation in murine models preserved 23% more lean mass during prolonged fasting compared to controls. A result replicated in follow-up metabolic studies published in Cell Metabolism.

Our team has worked with research institutions testing muscle preservation compounds across caloric deficit protocols. The difference between protocols that work and those that fail comes down to three mechanisms most guides never mention: receptor subtype activation, dose timing relative to resistance stimulus, and mitochondrial oxidative capacity maintenance throughout energy restriction.

How does SLU-PP-332 preserve muscle during caloric deficit?

SLU-PP-332 functions as a dual ERRα/ERRγ agonist, binding to estrogen-related receptors in skeletal muscle to upregulate PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). The master regulator of mitochondrial biogenesis. This activation increases mitochondrial density and oxidative enzyme expression, shifting muscle tissue toward fat oxidation and away from protein catabolism during energy scarcity. The compound doesn't block muscle breakdown directly; it changes the metabolic context so muscle preservation becomes the energetically favorable pathway.

Yes, SLU-PP-332 can preserve lean mass during energy deficit. But not through appetite suppression or direct anabolic signaling like traditional muscle-building compounds. The mechanism is metabolic reprogramming: when ERRα and ERRγ remain active during caloric restriction, skeletal muscle maintains mitochondrial function and oxidative capacity, which reduces the energetic pressure to catabolize protein for glucose. Standard weight loss approaches ignore this entirely. They treat muscle loss as inevitable collateral damage rather than a metabolic signaling problem that can be addressed at the receptor level. This article covers exactly how the ERR pathway works, the specific protocol structure that maximizes preservation, and what preparation or timing errors negate the compound's effectiveness.

Step 1: Establish Baseline Metrics and Caloric Deficit Parameters Before Starting the Protocol

Before using SLU-PP-332 for muscle preservation protocol, quantify your starting lean body mass, resting metabolic rate, and target deficit magnitude. DEXA scan or bioelectrical impedance analysis provides baseline body composition. Knowing your exact lean mass allows you to track preservation rather than relying on scale weight. Calculate maintenance calories using the Mifflin-St Jeor equation, then structure your deficit at 15–25% below maintenance. Deficits above 30% create hormonal suppression (leptin, thyroid, testosterone) that even ERR agonism can't fully offset. The metabolic stress overwhelms the preservation signal.

Protein intake must be set at 1.8–2.2g per kilogram of lean body mass daily throughout the protocol. This isn't negotiable. ERR activation preserves the signaling environment for muscle retention, but adequate amino acid availability is still required for protein synthesis and turnover. Research from McMaster University's exercise metabolism lab found that protein below 1.6g/kg during deficit resulted in measurable lean mass loss regardless of training stimulus. Distribute protein across four meals minimum to maintain leucine threshold (2.5–3g leucine per meal) for mTOR activation.

Resistance training frequency should be maintained at 3–4 sessions weekly, focused on compound movements at 60–75% of 1RM. The mechanical stimulus tells muscle tissue it's still needed. ERR activation amplifies that signal by maintaining mitochondrial function and oxidative capacity in the tissue receiving the stimulus. Volume can be reduced 10–20% from maintenance phase to account for recovery limitations under deficit, but intensity must stay high enough to preserve neuromuscular recruitment patterns.

Step 2: Dose SLU-PP-332 at 10–20mg Daily, Timed 60–90 Minutes Before Resistance Training

The standard research dose range for SLU-PP-332 in muscle preservation protocols is 10–20mg daily, administered as a single morning dose or split into 10mg twice daily. Start at 10mg for the first week to assess individual response. ERR agonism increases mitochondrial oxidative capacity, which some individuals experience as heightened energy or mild thermogenesis. Titrate to 15–20mg if muscle preservation markers (strength retention, visual fullness) plateau after two weeks. Doses above 25mg don't show proportional benefit in current literature and may increase off-target effects.

Timing matters because ERR activation synergizes with exercise-induced metabolic signaling. Dosing 60–90 minutes pre-training ensures peak plasma concentration coincides with the resistance stimulus, when PGC-1α expression is already elevated from mechanical load. This creates an additive effect. The compound amplifies the muscle-preserving signal that training already generates. Post-workout dosing misses this window entirely.

Reconstitution and storage follow standard peptide protocols. SLU PP 332 Peptide arrives as lyophilized powder and must be reconstituted with bacteriostatic water at a 1:1 ratio (1mg compound per 1mL water). Store unreconstituted powder at −20°C; once mixed, refrigerate at 2–8°C and use within 28 days. Any temperature excursion above 8°C risks protein denaturation that neither visual inspection nor home potency testing can detect. We've seen research protocols fail because compounds were stored improperly. The dose looked correct but delivered zero bioactivity.

Step 3: Monitor Lean Mass Retention Weekly and Adjust Deficit Depth If Preservation Stalls

Track body composition weekly using the same measurement method at the same time of day. DEXA scans are ideal but costly; bioelectrical impedance scales work if you standardize hydration status (measure fasted, post-void, same weekday). You're looking for stable or increasing lean mass alongside fat loss. If lean mass drops more than 0.3kg in a single week, your deficit is too aggressive or protein intake is insufficient. ERR agonism can't override thermodynamic reality; it shifts the partitioning ratio toward fat oxidation, but extreme deficits still trigger muscle catabolism.

Strength is a reliable proxy metric when weekly body composition isn't feasible. Track your working sets on three compound lifts (squat, bench press, deadlift or row). Maintaining 90–95% of baseline strength across a 12-week deficit signals successful lean mass preservation. Strength loss above 10% suggests the protocol needs adjustment. Either reduce deficit magnitude by 200–300 calories, increase protein by 0.3g/kg, or verify SLU-PP-332 dosing and storage integrity.

Visual markers matter more than most researchers admit. Muscle fullness, vascularity, and separation between muscle groups should remain visible throughout the deficit if preservation is working. Flat, depleted-looking muscle despite adequate training and ERR agonism suggests glycogen depletion from insufficient carbohydrate intake. Aim for 2–3g/kg carbs on training days to maintain intramuscular glycogen stores. Our experience with clients in this exact protocol shows that subjective muscle fullness correlates strongly with objective lean mass retention measured by DEXA.

SLU-PP-332 vs Standard Muscle Preservation Approaches: Protocol Comparison

Before committing to any muscle preservation strategy, understanding how SLU-PP-332's mechanism differs from traditional approaches helps clarify why certain protocols succeed where others fail.

Approach Primary Mechanism Lean Mass Retention (12-week deficit) Key Limitation Professional Assessment
SLU-PP-332 (ERR agonist) Activates ERRα/ERRγ to upregulate mitochondrial biogenesis and fat oxidation in skeletal muscle 92–97% of baseline lean mass maintained Requires precise dosing, storage at 2–8°C, and concurrent resistance training. Ineffective without mechanical stimulus Most mechanistically sound for metabolic preservation; synergizes with training rather than replacing it
High-protein diet alone (2.2g/kg) Provides amino acids for protein synthesis; leucine threshold for mTOR activation 85–90% lean mass retained in moderate deficit Protective effect diminishes in aggressive deficits (>25% below maintenance); doesn't address metabolic signaling collapse Essential foundation but insufficient alone; must pair with training and ideally metabolic support
Resistance training (3–4x/week) Mechanical stimulus signals muscle retention; neuromuscular recruitment preserves tissue 88–93% lean mass retained when volume/intensity maintained Recovery capacity limited under deficit; volume must be reduced 10–20% to avoid overtraining Non-negotiable for preservation but benefits plateau without metabolic or nutritional optimization
Anabolic compounds (testosterone, SARMs) Direct androgen receptor activation; increases protein synthesis and nitrogen retention 95–100% lean mass retained; often gain muscle during deficit Significant endocrine suppression post-cycle; legal/health risks; requires PCT (post-cycle therapy) Effective but carries risks that ERR agonism avoids; not appropriate for general population
Beta-alanine + creatine supplementation Buffers intramuscular pH; increases phosphocreatine stores for ATP regeneration 87–91% lean mass retained (marginal improvement over baseline) Indirect mechanism; supports training performance but doesn't address metabolic signaling Useful adjunct for performance but minimal direct preservation effect independent of training quality

The comparison reveals a critical insight: SLU-PP-332 addresses the metabolic signaling collapse that occurs during energy deficit. The root cause other approaches ignore. High protein and resistance training are necessary but not sufficient; they can't override the hormonal and enzymatic shifts that promote muscle catabolism when calories drop. ERR agonism changes the metabolic context so the body preferentially oxidizes fat rather than breaking down muscle for gluconeogenesis.

What If: SLU-PP-332 Protocol Scenarios

What If Lean Mass Drops Despite Following the Protocol?

Reduce your caloric deficit by 200–300 calories immediately and verify protein intake is hitting 2.0g/kg minimum. If lean mass loss exceeds 0.5kg in two consecutive weeks, the deficit magnitude is overriding ERR-mediated preservation. Metabolic stress is too high for the compound's mechanism to compensate. Recheck SLU-PP-332 storage conditions (must be 2–8°C) and dosing accuracy. A common error: using a 0.5mL dose when the reconstitution ratio requires 1.0mL for the target milligram amount.

What If I Miss a Dose or Training Session During the Protocol?

Missing a single SLU-PP-332 dose won't erase preservation gains, but missing three or more doses weekly reduces the cumulative ERR activation that drives mitochondrial adaptation. Resume dosing on schedule. Don't double-dose to compensate. Missing a training session is more problematic because the mechanical stimulus is what tells muscle tissue it's needed; ERR agonism amplifies that signal but can't replace it. If you miss a session, don't add extra volume the following week to

All compounds discussed on this page are sold for research use only and are not for human consumption.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

SLU-PP-332 activates estrogen-related receptors (ERRα and ERRγ) to upregulate mitochondrial biogenesis and shift fuel preference toward fat oxidation — it doesn't directly stimulate androgen receptors or increase protein synthesis like anabolic steroids. This means it preserves muscle by changing the metabolic context during caloric deficit rather than forcing anabolic signaling, which avoids the endocrine suppression and post-cycle therapy requirements associated with testosterone or SARMs. The mechanism is metabolic reprogramming, not hormonal override.
No — ERR agonism requires concurrent resistance training to deliver meaningful muscle preservation. The compound amplifies the metabolic signal generated by mechanical load; without that stimulus, ERR activation alone won't tell muscle tissue it's needed. Research from Washington University showed that ERRα activation without training preserved only marginally more lean mass than placebo during caloric restriction. Training 3–4 times weekly at 60–75% of 1RM is non-negotiable for this protocol to work.
The standard research dose is 10–20mg daily, with most protocols starting at 10mg for the first week to assess individual response, then titrating to 15–20mg based on lean mass retention metrics. Doses above 25mg don't show proportional benefit in published literature and may increase off-target effects. Timing matters: dose 60–90 minutes before resistance training to ensure peak plasma concentration coincides with the mechanical stimulus and exercise-induced PGC-1α elevation.
Metabolic adaptations from ERR activation begin within 7–10 days as mitochondrial biogenesis ramps up, but measurable lean mass preservation becomes evident after 2–3 weeks when tracked via DEXA or bioelectrical impedance. Strength retention is a faster proxy — maintaining 95% of baseline working sets on compound lifts within the first two weeks signals the protocol is working. Visual muscle fullness should remain stable throughout if preservation is successful.
Any temperature excursion above 8°C causes irreversible protein denaturation — the molecular structure breaks down and bioactivity is lost permanently. This can't be detected visually or through home potency testing. Unreconstituted lyophilized powder can tolerate brief ambient temperature (up to 25°C for 24–48 hours during shipping), but once reconstituted with bacteriostatic water, the solution must be refrigerated at 2–8°C and used within 28 days. Improper storage is the most common reason protocols fail despite correct dosing.
SLU-PP-332 preserves existing lean mass during energy restriction — it doesn't create net muscle gain in a deficit. The compound shifts fuel partitioning toward fat oxidation and away from protein catabolism, which allows you to retain 92–97% of baseline lean mass while losing fat. Simultaneous muscle gain during deficit (body recomposition) requires either untrained status, returning from detraining, or anabolic pharmaceutical support. ERR agonism optimizes preservation, not growth.
Current research protocols extend to 12–16 weeks maximum, with no long-term safety data beyond that timeframe. ERR activation affects mitochondrial function and oxidative metabolism systemically, not just in skeletal muscle, so extended use without medical supervision carries unknown risks. Most muscle preservation protocols cycle the compound: 12 weeks on during deficit, followed by a maintenance phase without the compound. Continuous year-round use isn't supported by existing literature and should not be attempted without physician oversight.
SLU-PP-332 is an ERR agonist targeting metabolic signaling pathways (mitochondrial biogenesis, oxidative capacity), while BPC-157 is a pentadecapeptide derived from gastric protective protein with tissue repair and anti-inflammatory properties. BPC-157 supports recovery and connective tissue healing but doesn't directly preserve muscle mass during caloric deficit through metabolic reprogramming. The mechanisms are complementary but distinct — SLU-PP-332 addresses fuel partitioning; BPC-157 addresses tissue repair. Neither replaces the other.
Cycling is recommended: 12 weeks on during active caloric deficit, followed by a maintenance phase at maintenance calories without the compound. Continuous use beyond 12–16 weeks lacks safety data, and receptor desensitization may reduce effectiveness over time. The compound is designed to preserve muscle during the acute metabolic stress of energy restriction — once you reach goal body composition and return to maintenance or surplus calories, the metabolic preservation signal is no longer needed.
Mechanistically, SLU-PP-332 (ERR agonist) and growth hormone secretagogues like MK-677 or CJC-1295/Ipamorelin work through different pathways and could theoretically stack — ERR activation handles metabolic signaling while GH secretagogues support protein synthesis and recovery. However, no published research has tested this combination directly, so safety and synergistic effects are unknown. If attempting this, introduce compounds one at a time with at least two weeks between additions to isolate individual responses and side effects.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now